{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-027568","form_type":"8-K/A","ticker":null,"cik":"0001600847","company_name":"Gamida Cell Ltd.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.765771+00:00","generated_at":"2026-06-04T05:21:37.280883+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Gamida Cell receives Nasdaq delisting notice; restructuring plan cancels all existing shares","bullets":["Nasdaq notified Gamida Cell on March 28, 2024, that shares will be delisted due to restructuring; trading suspended April 8; no appeal.","Restructuring converts $75M unsecured debt from Highbridge funds into 100% of company shares, cancelling all existing shares and options.","Existing shareholders may receive up to $27.5M in contingent value rights (CVRs) based on Omisirge revenue milestones and NK platform approval.","Lender will provide $50M exit financing: $30M on closing, plus conversion of ~$5M existing secured debt and $15M later.","Company will become private and deregister with SEC following court approval of creditors' arrangement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-027568","json":"https://secwatch.observer/filing/0001213900-24-027568.json","markdown":"https://secwatch.observer/filing/0001213900-24-027568.md","text":"https://secwatch.observer/filing/0001213900-24-027568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600847/000121390024027568/0001213900-24-027568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600847/000121390024027568/ea0202871-8ka1_gamida.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:21:37.280883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5d3ec1025a9c469556851c0aa92dfa744612d6a","claim":"Gamida Cell Ltd. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).","evidence_excerpt":"March 28, 2024, the Company received written notice (the “ Delisting Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Staff has, in accordance with Listing Rules 5101, 5110(b) and IM-5101-1, determined that the Company’s ordinary shares, par value NIS 0.01 per share (“ Ordinary Shares ”), will be delisted from Nasdaq based on the following factors: (i) the Restructuring Proceeding and the associated public interest concerns raised by such proceeding; (ii) concerns regarding the residual equity intere","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600847/000121390024027568/0001213900-24-027568-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Rules","value":"5101, 5110(b), IM-5101-1"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}